Author:
Li Qiyao,Xu Qun,Lo Nadine,Leeks Allan T.,Han Mark,Nefliu Marcela,Simpson John T.,Belsky Jennifer L.
Reference18 articles.
1. FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity. 〈https://www.fda.gov/news-events/press-announcements/fda-announces-voluntary-recall-several-medicines-containing-valsartan-following-detection-impurity〉, 07/13/2018.
2. The Nitrosamine “Saga”: Lessons Learned from Five Years of Scrutiny;Nudelman;Org. Process Res. Dev.,2023
3. Revisiting the landscape of potential small and drug substance related nitrosamines in pharmaceuticals;Burns;J. Pharm. Sci.,2023
4. Control of Nitrosamine Impurities in Human Drugs, U.S. FDA Guidance for Industry, February 2021. 〈https://www.fda.gov/media/141720/download〉.
5. Performance Characteristics of Mass Spectrometry-Based Analytical Procedures for Quantitation of Nitrosamines in Pharmaceuticals: Insights from an Inter-laboratory Study;Yang;J. Pharm. Sci.,2023
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献